Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Current and Emerging Treatment Options in Waldenström Macroglobulinemia: Anemia Is an Indication to Start Therapy, Bone Marrow Biopsy & Serum Immunofixation Electrophoresis to Confirm Diagnosis

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Meletios Dimopoulos
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Meletios Dimopoulos
139 views
November 19, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

10:06
ASCO 2022 Conference Coverage

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…

Feat. J. Abeykoon
13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
08:19
ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolera…

Feat. N. Shah
31:51
Indy Hematology Review

Managing Newly Diagnosed MM in 2023

Feat. S. Usmani
03:42
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation,…

Feat. G. Perini
24:53
Indy Hematology Review

Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…

Feat. M. Gertz
11:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Tr…

Feat. J. Castillo
28:28
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Manage Waldenstrom’s Macroglobulinemia in the…

Feat. S. Treon
03:40
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Long-Term Safety With ≥12 Months of Pirto…

Feat. C. Coombs
08:34
ASH 2022 Conference Coverage

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…

Feat. M. Shadman
21:29
Indy Hematology Review

Indy Hematology Review 2023: Emerging Therapies in Hematologic Malig…

Feat. R. Birhiray
25:45
Indy Hematology Review

Managing Newly Diagnosed Multiple Myeloma and Waldenstrom's Mac…

Feat. S. Usmani
51:44
PleXus Communications

Management of Waldenstrom's Macroglobulinemia in the Era of Tar…

Feat. S. Treon
23:36
MyCancerHaven

Experts Discuss the Basics of Diagnosis and Treatment of Waldenstrom…

Feat. R. Vij, J. Castillo
73:56
Indy Hematology Review

Indy Hematology Review 2023: Expert Case Discussions

Feat. M. Wiemann, S. Usmani, J. Mikhael, M. Lunning, S. Treon, T. Phillips, J. Woyach